By Mauro Orru
Novartis’s generics-and-biosimilars division Sandoz made a high-concentration formulation of its Hyrimoz injection available in the U.S., effectively entering the country’s immunology market.
The company made the announcement on Saturday, saying the Hyrimoz formulation is cleared to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and Crohn’s disease.
“This is an important moment for Sandoz and for the millions of patients living with chronic inflammatory diseases in the U.S.,” said Keren Haruvi, president of North America at Sandoz.
Last year, Novartis said it was planning to spin off Sandoz and list it as a stand-alone company in Switzerland, a move that would focus the once-sprawling healthcare conglomerate solely on prescription drugs. The proposed spinoff is expected to take place in the second half of the year.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
Read the full article here